杜永丽
职称：教授、硕士研究生导师
56net亚洲必嬴创新药物研究与开发中心主任
Email: yldu2016@163.com
教育背景：
1995-1999 山东师范大学化学系 化学教育 学士
2003-2008 中国科学院上海药物研究所 药物化学 博士
研究工作经历:
2008-2009 上海睿智化学有限公司 从事国际合作的创新药物研究开发工作
2010上半年 齐鲁制药有限公司 从事创新药物研究开发工作
2010.7-至今 56net亚洲必嬴化学与制药工程学院 从事教学与科学研究工作
研究方向：主要针对非小细胞肺癌、乳腺癌等恶性肿瘤进行靶向创新药物的研究与开发。重点进行创新药物先导化合物的发现与优化、计算机辅助药物设计、生物活性评价环节的研究开发工作。
代表性学术成果：
主持纵向项目：
1、国家自然科学基金，青年基金，批准号81202389，项目名称“新型选择性、功能活性PTP1B抑制剂的设计、合成及生物活性研究”，2013.01-2015.12。
2、国家自然科学基金，面上项目，批准号81872744，项目名称“新型ERR-alpha小分子反向激动剂的设计、合成及抗乳腺癌活性研究”，2019.01-2022.12。
3、山东省自然科学基金，面上项目，批准号ZR2019MH046, 2019.07-2022.06。
代表性论文及专利：
（1）Yongli Du*, Yanhui Zhang , Hao Ling , Qunyi Li, Jingkang Shen, Discovery of novel high potent and cellular active ADC type PTP1B inhibitors with selectivity over TCPTP via modification interacting with C site，European Journal of Medicinal Chemistry，2018，144，692-700, SCI.
（2）Yanhui zhang, Yongli Du*, The development of protein tyrosine phosphate- ase1B inhibitors defined by binding sites in crystalline complexes. Future Medicinal Chemistry 2018,10 (19 ), 2345-2367, SCI.
（3）Rui li, Yongli Du*, Zhipei Gao, Jingkang Shen, Molecular Modeling Studies on Carbazole Carboxamide Based BTK Inhibitors Using Docking and Structure-Based 3D-QSAR. International journal of molecular sciences 2018,19 (4). 1244, SCI.
（4）Rui li, Yongli Du*, Jingkang Shen, Molecular modelling studies on cinnoline -based BTK inhibitors using docking and structure-based 3D-QSAR. SAR and QSAR in environmental research 2018, 29 (11), 847-873, SCI.
（5）Yongli Du*, Lianhua Song, etc. The discovery of novel, potent ERR-alpha inverse agonists for the treatment of triple negative breast cancer.European Journal of Medicinal Chemistry, 2017,136: 457-467, SCI.
（6）Yang Ning, Haifei Chen, Yongli Du*, etc. A novel compound LingH2-10 inhibits the growth of triple negative breast cancer cells in vitro and in vivo as a selective inverse agonist of estrogen-related receptor α. Biomedicine & Pharmacotherapy. 93, 2017, 913–922, SCI.
（7）Haixing Guan, Yongli Du*, etc. A brief perspective of drug resistance toward EGFR inhibitors: the crystal structures of EGFRs and their variants. Future Medicinal Chemistry, 2017, 693-704, SCI.
（8）Haixing Guan, Yongli Du*, etc. Development of Selective Cyclin-Dependent Kinase 4 Inhibitors for Antineoplastic Therapies. Anticancer Agents in Medicinal Chemistry. 2017, 17(5): 646-657,SCI.
（9）Weiwei Han, Yongli Du*, Recent Development of the Second and Third Generation Irreversible Epidermal Growth Factor Receptor Inhibitors. Chemistry & Biodiversity. 2017, 14(7), SCI.
（10）Peihong Liu, Yongli Du*, Lianhua Song, Jingkang Shen, Qunyi Li, Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity, European Journal of Medicinal Chemistry, 2016, 118:27-33, SCI.
（11）Liudi Zhang, Peihong Liu, Haifei Chen, Qunyi Li, Lu Chen, Huijie Qi, Xiaojin Shi, Yongli Du*. Characterization of a selective inverse agonist for estrogen related receptor α as apotential agent for breast cancer. European Journal of Pharmacology. 789, 2016, 439-448,SCI.
（12）Yongli Du*, Hao Ling, Meng Zhang, Jingkang Shen, Qunyi Li, Discovery of novel, potent, selective and cellular active ADC type PTP1B inhibitors via fragment–docking-oriented de novel design, Bioorganic & Medicinal Chemistry, 2015,23: 4891 -4898, SCI.
（13）Peihong Liu, Yongli Du*, Lianhua Song, Jingkang Shen, Qunyi Li, Novel, potent, selective and cellular active ABC type PTP1B inhibitors containing (methane -sulfonyl-phenyl-amino)-acetic acid methyl ester phosphotyrosine mimetic，Bioorganic & Medicinal Chemistry, 2015, 23: 7079 -7088, SCI.
（14）Yongli Du, Qunli Li, Bing Xiong, Xin Hui, Xin Wang, Yang Feng, Tao Meng, Dingyu Hu, Datong Zhang, Mingwei Wang, Jingkang Shen, Aromatic β-amino-ketone derivatives as novel selective non-steroidal progesterone receptor antagonists. Bioorganic & Medicinal Chemistry 2010, 18 (12), 4255- 4268,SCI.
（15）Yongli Du, Qunyi Li, Bing Xiong, Xin Wang, Tao Meng, Dingyu Hu, Mingwei Wang, Jingkang Shen, The Discovery of Novel Non-steroidal Progesterone Receptor Antagonists. Abstract and poster on The 6th International Symposium for Chinese MedicinalChemists. 07. 2008.
（16）2008年07月于第六届世界华人药物化学会议上获奖：The presentation of Yongli Du, Qunyi Li et al entitled The Discovery of Novel Non-steroidal Progesterone Receptor Antagonists has achieved Poster Presentation Award of The 6th International Symposium for Chinese Medicinal Chemists.
（17）杜永丽，李群益，沈竞康，刘培红，新型取代磺酰胺类化合物、制备方法及其作为PTP1B抑制剂的用途，中国专利，CN2015104122426。
（18）杜永丽，沈竞康，李群益，凌浩，新型脲类蛋白酪氨酸磷酸酯酶1B抑制剂及其制备方法、药物组合物和用途，中国专利，CN2015102588258。
（19）杜永丽，沈竞康，李群益，刘培红，新型磺酰胺类化合物、制备方法及其作为蛋白酪氨酸磷酸酯酶1B抑制剂的用途，中国专利，CN2015104140693。
本科生教学：主讲药物化学、新药信息与文献检索等课程。
